TORRENT PHARMACEUTICALS LTD.

Torrent Pharmaceuticals Limited is implementing a voluntary recall of select batches of Semalix injection disposable pens (2 mg & 4 mg) as a precautionary measure. This action follows a product recall notification from their manufacturer, Dr. Reddy's Laboratories Ltd. (DRL), for technical evaluation. Torrent emphasizes that patient safety is paramount and there is no risk to patients currently on this treatment. Other Semaglutide products sold by Torrent, including oral formulations and different injection strengths/types manufactured by other entities, remain unaffected. Patients seeking clarification can contact pv@torrentpharma.com.

Torrent Pharmaceuticals Limited has announced the completion of its amalgamation with J. B. Chemicals & Pharmaceuticals Limited, effective July 8, 2026. The scheme, approved by the National Company Law Tribunal (NCLT) on July 6, 2026, was filed with the Registrar of Companies on July 8, 2026. Consequently, J. B. Chemicals & Pharmaceuticals Limited stands dissolved and amalgamated into Torrent Pharmaceuticals. The appointed date for the amalgamation is January 21, 2026. Following the amalgamation, Torrent Pharma's Memorandum of Association has been amended, increasing its authorized capital to ₹2,553,000,000, comprising 460,600,000 equity shares of ₹5 each and 2,500,000 preference shares of ₹100 each.

Torrent Pharmaceuticals Limited has announced the effective date of the scheme of amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The scheme, approved by the National Company Law Tribunal (NCLT) on July 6, 2026, became effective on July 8, 2026, after filing certified copies with the Registrar of Companies. J. B. Chemicals now stands amalgamated into Torrent Pharma. The appointed date for the amalgamation is January 21, 2026. Consequently, Torrent Pharma's capital clause in its Memorandum of Association has been amended to reflect the new structure, with authorized capital now at ₹2,553,000,000 divided into equity and preference shares.

Torrent Pharmaceuticals Ltd has announced the record date for its amalgamation with J.B. Chemicals & Pharmaceuticals Limited. Following the sanction by the Hon'ble National Company Law Tribunal, Ahmedabad Bench, the company has fixed Friday, July 17, 2026, as the Record Date. This date is for determining the shareholders of J.B. Chemicals who shall be entitled to receive fully paid-up equity shares of Torrent Pharma. The share exchange ratio is 51 fully paid-up equity shares of Torrent Pharma (face value of Rs. 5 each) for every 100 fully paid-up equity shares of J.B. Chemicals (face value of Re. 1 each). This disclosure is in accordance with SEBI Listing Regulations.

Torrent Pharmaceuticals Ltd has received the certified true copy of the final order from the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, sanctioning the Scheme of Amalgamation of J.B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. This order, dated July 6, 2026, was officially received by Torrent Pharma on July 7, 2026. The amalgamation was proposed under Sections 230 to 232 of the Companies Act, 2013. The company has made the order available on its website. This marks a significant step towards the completion of the merger process.

Torrent Pharmaceuticals Limited announced that the Hon'ble National Company Law Tribunal (NCLT), Ahmedabad Bench, has sanctioned the Scheme of Amalgamation of J. B. Chemicals & Pharmaceuticals Limited with Torrent Pharmaceuticals Limited. The order was pronounced on July 6, 2026. The amalgamation will become effective upon filing the certified copy of the order with the Registrar of Companies. The company will inform the stock exchanges about the effective date once the scheme is operational. This marks a significant step in the integration process between the two entities.

Torrent Pharmaceuticals Ltd has issued letters to shareholders without registered email addresses, providing a weblink to access the Notice of the 53rd Annual General Meeting and the Integrated Annual Report for FY 2025-26. The AGM is scheduled for June 23, 2026. This action complies with SEBI Listing Regulations, ensuring all shareholders can access crucial company information. Shareholders are encouraged to update their email addresses for future convenience.

Torrent Pharmaceuticals Ltd's board has recommended a final dividend of ₹9 (180%) per equity share of ₹5 each, to be paid around June 25, 2026, if declared by shareholders. An interim dividend of ₹29 per share was previously paid. The record date for the final dividend is May 29, 2026. The board also approved seeking approval for issuance of equity shares/convertible bonds/debentures via QIP or other modes, up to ₹5,000 crores, in the upcoming AGM. Audited financial results for the year ended March 31, 2026, were approved with an unmodified opinion.

Torrent Pharmaceuticals Ltd has fixed Friday, 29th May, 2026 as the record date for determining shareholders' eligibility for the final dividend for the financial year 2025-26, if declared by the company. This is pursuant to Regulation 42 of the Securities & Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Torrent Pharmaceuticals Ltd's board approved audited financial results for the year ended March 31, 2026, and recommended a final dividend of ₹9 per equity share. The board also approved seeking shareholder approval for issuance of equity shares/convertible bonds/debentures via QIP or other modes up to ₹5,000 crores. The final dividend, if declared, will be paid around June 25, 2026; record date is May 29, 2026.